137 related articles for article (PubMed ID: 38301349)
1. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
[TBL] [Abstract][Full Text] [Related]
2. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML
Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531
[TBL] [Abstract][Full Text] [Related]
3. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
[TBL] [Abstract][Full Text] [Related]
4. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
Michelsen B; Ørnbjerg LM; Kvien TK; Pavelka K; Nissen MJ; Nordström D; Santos MJ; Koca SS; Askling J; Rotar Z; Gudbjornsson B; Codreanu C; Loft AG; Kristianslund EK; Mann HF; Ciurea A; Eklund KK; Vieira-Sousa E; Yazici A; Jacobsson L; Tomšič M; Löve TJ; Ionescu R; van der Horst-Bruinsma IE; Iannone F; Pombo-Suarez M; Jones GT; Hyldstrup LH; Krogh NS; Hetland ML; Østergaard M
Rheumatology (Oxford); 2020 Sep; 59(9):2455-2461. PubMed ID: 31960053
[TBL] [Abstract][Full Text] [Related]
5. Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA.
Gaffney K; Gullick N; MacKay K; Patel Y; Sengupta R; Sheeran T; Hemmings L; Pamies P
Rheumatol Adv Pract; 2023; 7(3):rkad055. PubMed ID: 37663578
[TBL] [Abstract][Full Text] [Related]
6. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
[TBL] [Abstract][Full Text] [Related]
7. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Jacobsson L; Loft AG; Iannone F; Fagerli KM; Vencovsky J; Santos MJ; Möller B; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Cefle A; Eklund K; Codreanu C; Jones G; van der Sande M; Wallman JK; Sebastiani M; Michelsen B; Závada J; Nissen MJ; Sanchez-Piedra C; Tomšič M; Love TJ; Relas H; Mogosan C; Hetland ML; Østergaard M
J Rheumatol; 2024 Apr; 51(4):378-389. PubMed ID: 38224992
[TBL] [Abstract][Full Text] [Related]
9. Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis - data from the Danish nationwide DANBIO registry.
Mathew AJ; Glintborg B; Krogh NS; Hetland ML; Østergaard M
Semin Arthritis Rheum; 2022 Feb; 52():151948. PubMed ID: 35027245
[TBL] [Abstract][Full Text] [Related]
10. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
Michelsen B; Lindström U; Codreanu C; Ciurea A; Zavada J; Loft AG; Pombo-Suarez M; Onen F; Kvien TK; Rotar Z; Santos MJ; Iannone F; Hokkanen AM; Gudbjornsson B; Askling J; Ionescu R; Nissen MJ; Pavelka K; Sanchez-Piedra C; Akar S; Sexton J; Tomsic M; Santos H; Sebastiani M; Österlund J; Geirsson AJ; Macfarlane G; van der Horst-Bruinsma I; Georgiadis S; Brahe CH; Ørnbjerg LM; Hetland ML; Østergaard M
RMD Open; 2020 Sep; 6(3):. PubMed ID: 32950963
[TBL] [Abstract][Full Text] [Related]
11. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Lindström U; Pavelka K; Yilmaz N; Favalli EG; Nissen MJ; Michelsen B; Vieira-Sousa E; Jones GT; Ionescu R; Relas H; Sanchez-Piedra C; Tomšič M; Geirsson AJ; van der Horst-Bruinsma I; Askling J; Loft AG; Nekvindova L; Direskeneli H; Iannone F; Ciurea A; Fagerli KM; Santos MJ; Macfarlane GJ; Codreanu C; Eklund K; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Rusman T; Østergaard M; Hetland ML
J Rheumatol; 2023 Aug; 50(8):1009-1019. PubMed ID: 36455943
[TBL] [Abstract][Full Text] [Related]
12. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
Christiansen SN; Ørnbjerg LM; Rasmussen SH; Loft AG; Askling J; Iannone F; Zavada J; Michelsen B; Nissen M; Onen F; Santos MJ; Pombo-Suarez M; Relas H; Macfarlane GJ; Tomsic M; Codreanu C; Gudbjornsson B; Van der Horst-Bruinsma I; Di Giuseppe D; Glintborg B; Gremese E; Pavelka K; Kristianslund EK; Ciurea A; Akkoc N; Barcelos A; Sánchez-Piedra C; Peltomaa R; Jones GT; Rotar Z; Ionescu R; Grondal G; Van de Sande MGH; Laas K; Østergaard M; Hetland ML
Rheumatology (Oxford); 2022 Aug; 61(9):3799-3807. PubMed ID: 34940840
[TBL] [Abstract][Full Text] [Related]
13. Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
Dougados M; Lardy-Cléaud A; Desfleurs E; Claudepierre P; Goupille P; Ryussen-Witrand A; Saraux A; Tournadre A; Wendling D; Lukas C
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38428974
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis.
Weddell J; Din NRA; Harrison SR; Michelena X; McGonagle D; Barr A; Vandevelde C; Freeston J; Marzo-Ortega H
Rheumatol Adv Pract; 2024; 8(1):rkae018. PubMed ID: 38435412
[TBL] [Abstract][Full Text] [Related]
16. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A
Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis.
Kiltz U; Keininger DL; Holdsworth EA; Booth N; Howell O; Modi N; Tian H; Conaghan PG
Clin Rheumatol; 2022 Feb; 41(2):471-481. PubMed ID: 34800174
[TBL] [Abstract][Full Text] [Related]
19. Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries.
Mease PJ; Liu M; Rebello S; Kang H; Yi E; Park Y; Greenberg JD
Rheumatol Ther; 2019 Dec; 6(4):529-542. PubMed ID: 31529278
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Blachley T; Dube B; McLean RR; Kim N; Hur P; Ogdie A
J Rheumatol; 2022 Jul; 49(7):700-706. PubMed ID: 35428716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
